These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 7023829)

  • 21. Models for assessing the relationship between drug concentration and drug effect in performance horses.
    Kamerling SG; Owens JG
    Br Vet J; 1994; 150(6):507-25. PubMed ID: 7850442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Quantitative dependences for expressing the relationship between the pharmacological effect and the pharmacokinetic parameters of drugs].
    Mikhaĭlova D; Iamboliev I
    Eksp Med Morfol; 1982; 21(3):105-10. PubMed ID: 6756890
    [No Abstract]   [Full Text] [Related]  

  • 23. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.
    Muller PY; Milton M; Lloyd P; Sims J; Brennan FR
    Curr Opin Biotechnol; 2009 Dec; 20(6):722-9. PubMed ID: 19896825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of chirality on pharmacokinetics and pharmacodynamics.
    Crom WR
    Am J Hosp Pharm; 1992 Sep; 49(9 Suppl 1):S9-14. PubMed ID: 1530005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of pharmacokinetic-dynamic interrelations with special reference to applications in cardiovascular clinical pharmacology.
    de Mey C
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):665-74. PubMed ID: 7881706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target-mediated drug disposition and dynamics.
    Mager DE
    Biochem Pharmacol; 2006 Jun; 72(1):1-10. PubMed ID: 16469301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro measurements of metabolism for application in pharmacokinetic modeling.
    Lipscomb JC; Poet TS
    Pharmacol Ther; 2008 Apr; 118(1):82-103. PubMed ID: 18374419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaco-electroencephalography and pharmacokinetic/pharmacodynamic modeling in basic research: focus on human pharmacology.
    Valle M; Barbanoj MJ; Jané F
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl D():129-37. PubMed ID: 12575480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Basic concepts in pharmacology: important terms in pharmacodynamics and pharmacokinetics].
    Singer E
    Onkologie; 2008; 31 Suppl 2():21-4. PubMed ID: 18487864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling.
    Sung JH; Esch MB; Shuler ML
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical modeling of drug delivery.
    Siepmann J; Siepmann F
    Int J Pharm; 2008 Dec; 364(2):328-43. PubMed ID: 18822362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations.
    Lennernäs H
    Mol Pharm; 2009; 6(5):1429-40. PubMed ID: 19655809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On nonoscillation and monotonicity of solutions of nonnegative and compartmental dynamical systems.
    Chellaboina V; Haddad WM; Bailey JM; Ramakrishnan J
    IEEE Trans Biomed Eng; 2004 Mar; 51(3):408-14. PubMed ID: 15000372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basic principles of pharmacologic action.
    Schwertz DW
    Nurs Clin North Am; 1991 Jun; 26(2):245-62. PubMed ID: 2047284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of onset and offset of drug effect.
    Schnider TW; Minto CF
    Eur J Anaesthesiol Suppl; 2001; 23():26-31. PubMed ID: 11766242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.